To Evaluate the Safety and Efficacy of NVP-2203 Tablet in Patients

• Status: Not yet recruiting
• Trial end date: 2024-10-31
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to evaluate the efficacy and safety NVP-2203 in patients

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: NVP Healthcare

Criteria

Inclusion Criteria:

• Adults ≥ 19 years of age

• Primary hypercholesterolemia

• Subjects who have ability to comprehend the contents of study and before participating in trial and have willingness to sign of informed consent in writing

Exclusion Criteria:

• The subject not meet the specified LDL-C level

• Patients who were diagnosed with a malignant tumor within five years before Visit

• Inadequate subject for the clinical trial by the investigator's decision